SITC 29th Annual Meeting: Concurrent Session - High Throughput Technologies: Determinants of the Immune Response to CancerNovember 7-9, 2014Gaylord National Hotel & Convention Center National Harbor, MDSITC 29th Annual Meeting OrganizersArthur A. Hurwitz, PhD - National Cancer Institute Kim A. Margolin, MD - Stanford University Daniel E. Speiser, MD - Ludwig Center for Cancer Research of the University of Lausanne Walter J. Urba, MD, PhD - Earle A. Chiles Research Institute, Providence Cancer CenterProgram SummaryFrom the Society for Immunotherapy of Cancer (SITC), these enduring materials from the SITC 29th Annual Meeting on November 8, 2014 in National Harbor, MD focus on the development and use of high throughput methods for the analysis of cancer patients in an attempt to devise improved therapeutic cancer treatment. These methods include whole exome sequencing of tumor DNA in order to identify immune targets, whole genome sequencing of patient DNA to identify genetic variants associated with cancer susceptibility, as well as single cell analysis of infiltrating lymphocytes. Integration of results from these as well as related studies will hopefully lead to improved cancer diagnosis as well as treatment, which was also discussed. About the SITC 29th Annual MeetingThe SITC 29th Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, oral and poster abstract presentations, and ample opportunities for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important society projects. #ClinicalTrials #Melanoma #PresentationSlides #Video #AnnualMeeting #SITC #AdoptiveCellTherapy #Ipilimumab #Clinician #Industry #Oncologist #Researcher #2014
Meeting: SITC 29th Annual Meeting; Session: Concurrent Session — High Throughput Technologies: Determinants of the Immune Response to Cancer; Presentation: Single Cell Functional Analysis Provides Insights into Cancer Patient Responses, including the Development of Resistance, to Cell-Based and Combination Immunotherapies; Presenter: James R. Heath, PhD – California Institute of Technology; Date: November 8, 201400:22:45
Meeting: SITC 29th Annual Meeting; Session: Concurrent Session — High Throughput Technologies: Determinants of the Immune Response to Cancer; Presentation: T Cell Receptor Diversity Evaluation to Predict Patient Response to Ipilimumab in Metastatic Melanoma; Presenter: Michael Postow, MD – Memorial Sloan-Kettering Cancer Center; Date: November 8, 201400:16:29
Meeting: SITC 29th Annual Meeting; Session: Concurrent Session — High Throughput Technologies: Determinants of the Immune Response to Cancer; Presentation: Use of High Throughput Sequencing to Identify Mutated Tumor Antigens; Presenter: Paul F. Robbins, PhD – National Institutes of Health/National Cancer Institute; Date: November 8, 201400:30:32